Unresectable Gallbladder Carcinoma Completed Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0046852 (Unresectable Gallbladder Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01093222Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaTreatment